Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
Authors:
Open Access
- 15 November 2022
- journal article
- abstracts
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 557-560